Trial · NCT01238861
Results by group126
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 126
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Annual Asthma Exacerbation Rate (AER) for Eosinophilic Phenotype (EOS+) Participants | Eosinophilic Phenotype (EOS+) Placebo | 0.57 | AER events/person-year | ||
| Annual Asthma Exacerbation Rate (AER) for Eosinophilic Phenotype (EOS+) Participants | EOS+ Benralizumab, 2 mg | 0.65 | AER events/person-year | ||
| Annual Asthma Exacerbation Rate (AER) for Eosinophilic Phenotype (EOS+) Participants | EOS+ Benralizumab, 20 mg | 0.37 | AER events/person-year | ||
| Annual Asthma Exacerbation Rate (AER) for Eosinophilic Phenotype (EOS+) Participants | EOS+ Benralizumab, 100 mg | 0.34 | AER events/person-year | ||
| Minimum Observed Serum Trough Concentration for Benralizumab at Steady-State (Ctrough, ss) | EOS+ Benralizumab, 2 mg | 34.7 | Standard Deviation 131 | microgram per milliliter | |
| Minimum Observed Serum Trough Concentration for Benralizumab at Steady-State (Ctrough, ss) | EOS+ Benralizumab, 20 mg | 182 | Standard Deviation 180 | microgram per milliliter | |
| Minimum Observed Serum Trough Concentration for Benralizumab at Steady-State (Ctrough, ss) | Benralizumab, 100 mg | 869 | Standard Deviation 665 | microgram per milliliter | |
| Dose-Normalized Minimum Observed Serum Trough Concentration for Benralizumab at Steady-State (Ctrough, ssD) | EOS+ Benralizumab, 2 mg | 17.3 | Standard Deviation 65.3 | microgram per milliliter | |
| Dose-Normalized Minimum Observed Serum Trough Concentration for Benralizumab at Steady-State (Ctrough, ssD) | EOS+ Benralizumab, 20 mg | 9.10 | Standard Deviation 9.02 | microgram per milliliter | |
| Dose-Normalized Minimum Observed Serum Trough Concentration for Benralizumab at Steady-State (Ctrough, ssD) | Benralizumab, 100 mg | 8.69 | Standard Deviation 6.65 | microgram per milliliter | |
| Percentage of Participants With Anti-Drug Antibodies (ADA) to Benralizumab in Eosinophilic Phenotype (EOS+) Participants | EOS+ Placebo | 3.8 | percentage of participants | ||
| Percentage of Participants With Anti-Drug Antibodies (ADA) to Benralizumab in Eosinophilic Phenotype (EOS+) Participants | EOS+ Benralizumab, 2 mg | 42.0 | percentage of participants | ||
| Percentage of Participants With Anti-Drug Antibodies (ADA) to Benralizumab in Eosinophilic Phenotype (EOS+) Participants | EOS+ Benralizumab, 20 mg | 30.9 | percentage of participants | ||
| Percentage of Participants With Anti-Drug Antibodies (ADA) to Benralizumab in Eosinophilic Phenotype (EOS+) Participants | EOS+ Benralizumab, 100 mg | 25.6 | percentage of participants | ||
| Change From Baseline in Asthma Control Questionnaire (6-items) (ACQ-6) Score at Week 52 | EOS+ Placebo | Baseline (n=80,80,80,82,142,140) | 2.7479 | Standard Deviation 0.9762 | units on a scale |
| Change From Baseline in Asthma Control Questionnaire (6-items) (ACQ-6) Score at Week 52 | EOS+ Benralizumab, 2 mg | Baseline (n=80,80,80,82,142,140) | 2.6479 | Standard Deviation 0.9908 | units on a scale |
| Change From Baseline in Asthma Control Questionnaire (6-items) (ACQ-6) Score at Week 52 | EOS+ Benralizumab, 20 mg | Baseline (n=80,80,80,82,142,140) | 2.4750 | Standard Deviation 0.9106 | units on a scale |
| Change From Baseline in Asthma Control Questionnaire (6-items) (ACQ-6) Score at Week 52 | EOS+ Benralizumab, 100 mg | Baseline (n=80,80,80,82,142,140) | 2.5346 | Standard Deviation 0.9728 | units on a scale |
| Change From Baseline in Asthma Control Questionnaire (6-items) (ACQ-6) Score at Week 52 | EOS- Placebo | Baseline (n=80,80,80,82,142,140) | 2.4742 | Standard Deviation 0.8408 | units on a scale |
| Change From Baseline in Asthma Control Questionnaire (6-items) (ACQ-6) Score at Week 52 | EOS- Benralizumab, 100 mg | Baseline (n=80,80,80,82,142,140) | 2.6381 | Standard Deviation 0.8330 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01238861/results